Xintela signs memorandum of understanding with CO.DON

Xintela AB (publ) announces today that the company has signed a non-binding Memorandum of Understanding with the leading European cell therapy company, CO.DON. The parties intend to collaborate on the development of Xintela’s quality markers for CO.DON’s next cell-based product and for the co- development of Xintela’s stem cell product for the treatment of osteoarthritis. […]

Xintela strengthens business development and reorganizes

Xintela announces today that Thomas Areschoug has been recruited to the business development team as Business Development Manager. In addition, the company is reorganizing in order to develop its projects more efficiently. – We are very pleased to have Thomas Areschoug join the team. His broad international network and experience is exactly what Xintela now […]

Xintela reports positive preclinical results in cancer project

Xintela AB (publ) today announces an update of the company’s projects in regenerative medicine and cancer. All projects are developing in a positive way. New results from the cancer project show that Xintela’s targeting antibody kills glioblastoma cells both in cell studies and in an animal model. Significant progress in the treatment of the brain […]

Xintela’s stem cells show positive treatment effects on cartilage damage in horse study

Xintela AB (publ), announces today that the company’s selected stem cells have beneficial effects on joint cartilage and underlying bone in post- traumatic osteoarthritis, based on additional analysis of the company’s horse study and the final report from Cornell University, Ithaca, New York. The results are very promising for Xintela’s development of stem cell therapy […]

Xintela reports positive results from completed horse study

Xintela AB (publ), announces today that the company’s completed horse study met its primary endpoint, demonstrating that Xintela’s stem cells are safe. Xintela can now take the next step in the development of an effective, safe stem cell product for the treatment of cartilage damage and osteoarthritis. “We are very pleased to report a positive […]

Xintela’s Focus in the Cancer Arena

XINMARK is Xintela’s patented integrin technology platform that is being developed with the aim of commercialising innovative and improved treatments in two main areas: regenerative medicine and cancer. Within the cancer arena, Xintela’s research focuses on glioblastoma, an aggressive brain tumour, and this newsletter provides an update on our progress to date.

Focus on commercial development

As our projects progress, it is important to ensure that we have the right competencies to take them towards commercialisation. We are therefore delighted to start the Autumn with two new employees who will strengthen the company’s commercial team. Lina Boreson, with extensive experience from the pharmaceutical industry as, amongst other roles, Head of Marketing, […]

Xintela recruits Rickard Mosell as Head of Business Development

On 12 September 2016, Xintela announces that Rickard Mosell has been recruited as Head of Business Development from October 1, 2016. Rickard Mosell will leave his current position as CEO of Ideon Innovation and will be responsible for Xintela’s business development and financing. Rickard Mosell will also be a member of Xintela’s management team. Rickard […]

Xintela receives 1,5 MSEK in dispute settlement

Xintela today announces that it has settled a dispute and will receive 1,500,000 Swedish Crowns in compensation. The background to the dispute is that the counter party, who had an assignment from Xintela to validate one of the company’s patents, missed the deadline for validation with the consequence that the patent was not validated in […]